Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Open access
Johnson, Daniel H, Zobniw, Chrystia M, Trinh, Van A, Ma, Junsheng, Bassett, Roland L, Abdel-Wahab, Noha, Anderson, Jaime, Davis, Jennifer E, Joseph, Jocelyn, Uemura, Marc, Noman, Ali, Abu-Sbeih, Hamzah, Yee, Cassian, Amaria, Rodabe, Patel, Sapna, Tawbi, Hussein, Glitza, Isabella C, Davies, Michael A, Wong, Michael K, Woodman, Scott, Hwu, Wen-Jen, Hwu, Patrick, Wang, Yinghong, Diab, Adi · 2018 · Journal for ImmunoTherapy of Cancer

Abstract

BACKGROUND: Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α inhibitors such as infliximab (IFX) may expedite symptom resolution and shorten CS duration. Thus, we conducted the first retrospective study, to our knowledge, evaluating symptom resolution in patients with irEC treated with and without IFX. METHODS: Data were collected from the medical records of patients diagnosed with irEC. The primary endpoint was time to symptom resolution for irEC for cases managed with IFX plus CS (IFX group) versus CS alone (CS group). Duration of CS, overall survival (OS), and time to treatment failure (TTF) were secondary endpoints. RESULTS: Among 75 patients with irEC, 52% received CS alone, and 48% received IFX. Despite higher grade colitis in the IFX group (grade 3/4: 86% vs. 34%; p < 0.001), median times to diarrhea resolution (3 vs. 9 days; p < 0.001) and to steroid titration (4 vs. 13 days; p < 0.001) were shorter in the IFX group than in the CS group without a negative impact on TTF or OS. Total steroid duration (median 35 vs. 51 days; p = 0.150) was numerically lower in the IFX group. CONCLUSIONS: Despite higher incidence of grade 3/4 colitis, IFX added to CS for the treatment of patients with irEC was associated with a significantly shorter time to symptom resolution. The data suggest that early introduction of IFX should be considered for patients with irEC until definitive prospective clinical trials are conducted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-018-0412-0

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 194

Metadata

Authors
Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel-Wahab, N., Anderson, J., Davis, J. E., Joseph, J., Uemura, M., Noman, A., Abu-Sbeih, H., Yee, C., Amaria, R., Patel, S., Tawbi, H., Glitza, I. C., Davies, M. A., Wong, M. K., Woodman, S., Hwu, W.-J., Hwu, P., Wang, Y., & Diab, A.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2018-10-11
Volume
6
Issue
1
Pages
103-103
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2897516580
Cited by
194
References
14
FWCI
7.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. https://app.cochat.ai/papers/10.1186/s40425-018-0412-0
The paper
Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel-Wahab, N., Anderson, J., Davis, J. E., Joseph, J., Uemura, M., Noman, A., Abu-Sbeih, H., Yee, C., Amaria, R., Patel, S., Tawbi, H., Glitza, I. C., Davies, M. A., Wong, M. K., . . . Diab, A. (2018). Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0412-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.